This stock is no longer traded. It was delisted on July 9, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing precision immunodiagnostic agents and immunotherapeutics. Its primary function is to enhance the ability to accurately identify and treat diseases, specifically through its proprietary technology based on the Manocept platform. This platform is designed to target and illuminate cells with high-level receptor activity, making it particularly significant in the fields of oncology, rheumatology, and neurology. Notable developments include its diagnostic products which address unmet medical needs by improving diagnostic accuracy and patient outcomes. Navidea Biopharmaceuticals is strategically positioned within the biotechnology sector, emphasizing innovation in detecting and managing conditions such as rheumatoid arthritis and various types of cancer. By leveraging its unique technological advancements, the company plays a crucial role in enhancing diagnostic imaging and therapeutic interventions, contributing to the overall progress and precision of medical treatments available in the market.
Website4995 Bradenton Avenue
Dublin, OH, 43017-3552
United States
Summary of Jun 21's posts. Generated by AI.
Summary of Oct 6's posts. Generated by AI.
Summary of Jun 22's posts. Generated by AI.
Investors talking about NAVB also mention these. Each card shows that asset’s own numbers for the past 24 hours.